19,498 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Purchased by Virtu Financial LLC

Virtu Financial LLC bought a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 19,498 shares of the company’s stock, valued at approximately $175,000.

Other hedge funds also recently modified their holdings of the company. Swiss National Bank raised its stake in shares of Travere Therapeutics by 7.0% during the third quarter. Swiss National Bank now owns 147,600 shares of the company’s stock worth $1,320,000 after buying an additional 9,700 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Travere Therapeutics by 4.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 565,919 shares of the company’s stock valued at $5,059,000 after purchasing an additional 25,566 shares during the last quarter. Invesco Ltd. lifted its stake in Travere Therapeutics by 16.2% in the third quarter. Invesco Ltd. now owns 813,252 shares of the company’s stock valued at $7,270,000 after buying an additional 113,250 shares during the period. Hsbc Holdings PLC boosted its holdings in Travere Therapeutics by 101.5% during the third quarter. Hsbc Holdings PLC now owns 43,877 shares of the company’s stock worth $404,000 after buying an additional 22,106 shares during the last quarter. Finally, Dark Forest Capital Management LP bought a new position in Travere Therapeutics during the third quarter worth about $251,000.

Wall Street Analyst Weigh In

Several research firms recently weighed in on TVTX. Guggenheim reissued a “neutral” rating on shares of Travere Therapeutics in a research note on Wednesday, March 27th. Wedbush restated an “outperform” rating and issued a $13.00 price objective on shares of Travere Therapeutics in a research report on Wednesday, April 17th. Canaccord Genuity Group lifted their target price on Travere Therapeutics from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. Finally, HC Wainwright restated a “buy” rating and issued a $19.00 price target on shares of Travere Therapeutics in a report on Tuesday, May 7th. Five research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Travere Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $15.58.

Travere Therapeutics Stock Performance

Shares of TVTX opened at $7.31 on Monday. The stock has a market capitalization of $556.50 million, a price-to-earnings ratio of -3.48 and a beta of 0.78. Travere Therapeutics, Inc. has a 12 month low of $5.12 and a 12 month high of $17.57. The firm has a fifty day simple moving average of $6.56 and a 200 day simple moving average of $7.72. The company has a current ratio of 2.78, a quick ratio of 2.75 and a debt-to-equity ratio of 5.10.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Monday, May 6th. The company reported ($1.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.78). The business had revenue of $41.40 million for the quarter, compared to analyst estimates of $43.46 million. Travere Therapeutics had a negative return on equity of 238.06% and a negative net margin of 87.94%. The company’s quarterly revenue was up 34.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.27) earnings per share. Research analysts forecast that Travere Therapeutics, Inc. will post -3.77 EPS for the current fiscal year.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.